Table 1. The b/a and x/a ratios (%) as markers of site-occupancy and sialylation, respectively, of genetically diagnosed patients.

CDG type	b/a	x/a
PMM2	123.0*	0
ALG14	8.8*	1.5
SLC35A1	2.3	21.1*
SLC35A2	1.5	16.2*
PGM1	27.3*	7.8*
MAN1B1	0	0

The calculation is based on the ESI-Q mass spectrum in Fig. 7.

*significantly increased.